The possibility of the secondary ineffectiveness of biological drugs due to production of antibodies for them, especially anti-TNF-α agents, should be considered because severe HA20 patients complicated with autoimmune diseases are expected to have both autoinflammatory conditions and increased antibody production. The gene discussed is TNF; the disease is A20 haploinsufficiency.